Skip to main content

Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer

Abstract

Background

The purpose of these studies was to compare efficacy and toxicity of docetaxel alone with the combination of gemcitabine and docetaxel for treatment of metastatic esophageal carcinoma.

Patients and methods

These studies enrolled patients with histopathologically verified squamous cell carcinoma or adenocarcinoma of the esophagus or cardia. Between March 1997 and June 1999, 52 patients were enrolled in the initial Phase II study (Study 1). They were scheduled for treatment with docetaxel 100 mg/m2 every third week as a 1-h infusion. The second Phase II study between September 2000 and March 2003 included 65 patients (Study II). They were given docetaxel 30 mg/m2, administered as a 30-min i.v. infusion weekly for four times, followed by 2 weeks of rest, and gemcitabine starting with a dose of 750 mg/m2 (if well-tolerated 1,000 mg/m2) on days 1 and 15, followed by 3 weeks of rest. A new cycle began on day 36. Patients were premedicated with betamethasone 8 mg p.o. on the evening before, and 8 mg i.v. 30–60 min before the docetaxel infusion. Response was confirmed by computed tomography and assessed at 12 and 24 weeks. Toxicity was assessed according to WHO scales.

Results

In study I, 38 out of the 52 enrolled patients were valuable. Two patients experienced complete remission (CR) (5%), 10 patients partial remission (PR) (26%), nine patients stable disease (SD) (24%), and 17 patients showed progressive disease (PD) (45%). Toxicity mainly involved leukopenia, which in some cases required hospitalization and treatment with antibiotics. In Study II, 46 out of the 65 enrolled patients (70%) were assessable. Out of these, three patients (7%) had CR, eight patients (17%) had PR, 10 patients (22%) had SD, and 25 (54%) PD. Overall response was 24% while an additional 22% showed stable disease. Toxicity mainly consisted of leucopenia and pain.

Conclusion

Docetaxel as a single agent is active in esophageal cancer, both in treatment naive and in previously treated patients with recurrent disease. The overall response rate was 31%, with a good-safety profile. The addition of gemcitabine is well tolerated, but adds no efficacy. Weekly administration of docetaxel may be less effective. It demonstrates moderate efficacy and the doses used provide an acceptable safety profile.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Mantravadi R, Lad T, Briele H, Liebner EJ. Carcinoma of the esophagus: sites of failure. Int J Radiat Oncol Biol Phys 1982;8(11):1897–1901.

    PubMed  CAS  Google Scholar 

  2. 2.

    Mandard AM et al. Autopsy findings in 111 cases of esofhageal cancer. Cancer 1981;48:329–35.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Anderson L, Lad T. Autopsy findings in squamous cell carcinoma of the esophagus. Cancer 1982;50:1587–90.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Attah E, Hadju S. Benign and malignant tumors of the esophagus at autopsy. J Thoracic Cardiovasc surg 1968;55(3):396–404.

    CAS  Google Scholar 

  5. 5.

    Bosch A, Frias Z, Caldwell W, Jaeschke WH. Autopsy findings in carcinoma of the esophagus. Acta Radiol Oncol 1979;18:103–12.

    CAS  Google Scholar 

  6. 6.

    Roth JA, Putman SB, Rich TA, Forastiere AA. In: De Vita V Jr. Hellman S, Rosenber S, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott, 1997;980–1021.

  7. 7.

    Bleiberg H, Conroy T, Paillot B et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216–20.

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Salts L, Kelson D. Combined modality therapy in the treatment of locoregional oesophageal cancer. Ann Oncol 1992;3:793–9.

    Google Scholar 

  9. 9.

    Iizuka T et al. Phase II study of CDDP + 5-FU for squamous esophageal carcinoma. JEOG cooperative study results. Proc Am Soc Clin Oncol 1991;10:157.

    Google Scholar 

  10. 10.

    Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol 2005;32(2 Suppl 4):S39–51.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Safran H et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22(5):670–7.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Ajani JA et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Nat Cancer Inst 1994;86:1086–91.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Muro K et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15(6):955–9.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancer. Cancer Invest 2003;21(6):887–96.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Kulke MH et al. A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 2006;24(4):346–50.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal and esophageal cancers. Cancer 2006;107(2):221–31.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Enzinger PC et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50(12):2218–23.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;16(14 suppl 14):22–5.

    Google Scholar 

  20. 20.

    Pozzo C et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15(12):177–81.

    Article  Google Scholar 

  21. 21.

    Airoldi M et al. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 2003;20(1):19–24.

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Wittes RE, Adrianza ME, Parsons R et al. Compilation of phase II results with single antineoplastic agents. Cancer Treat Symp 1985;4:91–130.

    Google Scholar 

  23. 23.

    Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with Cisplatin and 5-fluorouracil. Radiother Oncol 1988;13(1):41–6.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to M. Albertsson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Albertsson, M., Johansson, B., Friesland, S. et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol 24, 407–412 (2007). https://doi.org/10.1007/s12032-007-0028-6

Download citation

Keywords

  • Metastatic
  • Esophageal
  • Squamous cell carcinoma
  • Adenocarcinoma
  • Chemotherapy
  • Docetaxel
  • Gemcitabine
  • Esophageal cancer